Clinical trial
This Study Will Examine the Effects of GSK256066 to Protect Mild Steroid-naive…
NCT00445510 · GlaxoSmithKline, Industry · Completed
Key facts
| NCT number | NCT00445510 |
|---|---|
| Title | This Study Will Examine the Effects of GSK256066 to Protect Mild Steroid-naive Asthmatics Against an Antigen Challenge |
| Official title | A Double Blind, Placebo Controlled, Repeat Dose Study to Determine the Effect of GSK256066 87.5 Mcg to Protect Against AMP Challenge in the Lung in Mild Steroid-naive Asthmatics. |
| Lead sponsor | GlaxoSmithKline, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Asthma |
| Intervention type | Drug |
| Interventions | GSK256066 |
| Enrollment | 24 |
| Start date | Jun 1, 2006 |
| First posted | Mar 9, 2007 |
| Last update posted | Jun 4, 2012 |
| Countries | New Zealand |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: